Articles and Insights About Wearables for Clinical Trials

Stijn Rogiers Interview About Accelerating Digital Endpoints

Posted by Stijn Rogiers on May 26, 2022

SAS Principal Industry Consultant Stijn Rogiers interviewed VivoSense CEO Dudley Tabakin about the uptake in decentralized clinical trials in response to the ongoing disruptions caused by the Coronavirus pandemic of 2020. As trials move toward decentralization, new processes and strategies are required to effectively collect and analyze patient data in a meaningful and validated way. Here are a few key takeaways from their conversation.

Read More

Pharmaphorum Interview: Accelerating Wearables in Clinical Trials

Posted by pharmaphorum on May 11, 2022

Pharmaphorum interviewed VivoSense CEO Dudley Tabakin and new board members from Xontogeny and Debiopharm to discuss how VivoSense’s recent $25M Series A Financing round will help scale up VivoSense® software and accelerate the use of wearable sensors data in clinical trials.

Read More

Digital Biomarkers: Pandemic Impact, Barriers, Trends, Hype, and Hope

Posted by Kate Lyden on April 26, 2022

Joao Bocas, a keynote speaker and social media influencer for digital health technology, interviewed Kate Lyden, Chief Science Officer at Vivosense, to discuss trending topics surrounding the transformation of moving clinical trials into the real world. They talked about the impact of the pandemic, barriers to adoption, therapeutic areas that can benefit, and some of the hype and hope of novel digital biomarker development.

Read More

Digital Health Expert, Rob Wilson, Joins VivoSense Leadership Team

Posted by Dudley Tabakin on April 6, 2022

Vivosense is pleased to announce that Rob Wilson has joined the company as VP of Marketing Strategy. He brings more than 30 years of expertise in strategic planning, finance, and business development for a wide range of companies in digital health, biotechnology, medical technology, and healthcare service industries.

Read More

VivoSense Announces Closing of $25M Series A Financing

Posted by Dudley Tabakin on March 30, 2022

Proceeds to accelerate the collection and use of wearable sensor data in clinical trials along with the development of novel digital biomarkers.

Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund.

NEWPORT BEACH, Calif. – March 30, 2022-- VivoSense, Inc., (“VivoSense”) an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data, today announced the close of a $25 Million Series A financing round. The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments (COAs). VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital COAs for life science research.

Read More

How to Visualize Physiological Data for Clinical Trials Using VivoSense®

Posted by Dudley Tabakin on February 10, 2022

The best way to understand how VivoSense®️ software can help you visualize physiological data from your clinical trial is to see it in action. The first video below will take you through the graphical user interface, importing and opening a physiological data session, and exploring the data with the Data Explorer panel and the synchronized chart panel.

The second video will discuss some advanced tools, such as the channel chart and plot properties, create some save layouts for use with all data sessions, create annotation markings to identify events in the data, and export the data to ASCII.

Read More

Employee Spotlight: Patrick Hankey, PhD.

Posted by VivoSense Team on January 28, 2022

Our Employee Spotlight series highlights a different team member each month, offering a behind-the-scenes look at the people integral to our success. This month, we are speaking with one of our company founders, Patrick Hankey, PhD., VP of Business Development.

Read More

Catalyze Digital Biomarker Innovation Through Collaboration

Posted by Kate Lyden on January 27, 2022

Industry and academia each play important roles in advancing wearable technologies and digital biomarkers to develop life-changing drugs and therapies. Still, successful relationships between the two groups are not nearly as prevalent as they could – or should – be. In this presentation, Kate Lyden, VivoSense Chief Science Officer, discusses the motivation for academia and industry to work together, where the overlap lies, and opportunities for moving forward together.

Read More

Advancing Novel Respiratory Endpoint Discovery with Wearables

Posted by VivoSense Team on January 18, 2022

The adoption of wearables into clinical trials is fostering innovative ideas about novel digital biomarker development. The following articles discuss strategies for developing respiratory endpoints using real-world data and a patient-centered approach. Learn more and advance ideas for your next research project!

Read More

Digital Biomarkers: Current Limitations and Future Outlook

Posted by Kate Lyden on December 23, 2021

There’s an undeniable push to drive innovation for a new age of precision medicine. At the 2021 Digital Biomarkers & Digital Measurements Summit, Kate Lyden, VivoSense Chief Science Officer, joined a panel of experts to discuss the future of digital biomarkers and advancing medicine toward a patient-oriented, decentralized, tech-enabled approach. Here is a quick snap-shot of her key takeaways.

Read More

Subscribe to Email Updates

Stay Connected

Popular